Grifols (GRFS) Depreciation & Amortization (CF) (2010 - 2013)
Grifols (GRFS) reported Depreciation & Amortization (CF) of $40970.5 for Q1 2013, down 1.03% on a YoY basis from $41398.2 in Q1 2012, and down 1.03% quarter-over-quarter from $41398.2 in Q1 2012.
Grifols (GRFS) Depreciation & Amortization (CF) (2010 - 2013) Analysis & Trends
Grifols has reported Depreciation & Amortization (CF) for 4 years, with the latest figure at $40970.5 in Q1 2013.
- For the quarter ending Q1 2013, Depreciation & Amortization (CF) fell 1.03% year-over-year to $40970.5; the trailing twelve-month figure through Dec 2013 stood at $40970.5 (down 1.03% YoY), and the FY2025 full-year result was $523.8 million, up 11.92% from the prior year.
- Depreciation & Amortization (CF) for Q1 2013 stood at $40970.5, down from $41398.2 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $122.2 million in Q4 2011, with the low at $40970.5 in Q1 2013.
- Historically, Depreciation & Amortization (CF) has averaged $46.1 million across 4 years, with a median of $31.1 million in 2010.
- Annual changes were most pronounced in 2011 — Depreciation & Amortization (CF) surged 96.51% — and 2013, when it slipped 1.03%.
- Grifols' Depreciation & Amortization (CF) stood at $62.2 million in 2010, then surged by 96.51% to $122.2 million in 2011, then slumped by 99.97% to $41398.2 in 2012, then declined by 1.03% to $40970.5 in 2013.
- The last three Depreciation & Amortization (CF) figures came in at $40970.5 (Q1 2013), $41398.2 (Q1 2012), and $122.2 million (Q4 2011), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 509.00 Mn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 2.00 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 188.00 Mn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 581.00 Mn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 1.12 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 93.00 Mn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 1.61 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 594.00 Mn |
| 10 | Grifols | 6.05 Bn | 5.09 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2013 | 40,970.52 |
| Mar 31, 2013 | 40,970.52 |
| Mar 31, 2012 | 41,398.23 |
| Mar 31, 2012 | 41,398.23 |
| Dec 31, 2011 | 122.15 Mn |
| Dec 31, 2011 | 122.15 Mn |
| Dec 31, 2010 | 62.16 Mn |
| Dec 31, 2010 | 62.16 Mn |